MyFinsight
Home
Blog
About
Contact
Download
Download image
Comprehensive loss
-$105,906K
(-22.21%↓ Y/Y)
Interest income
$7,872K
Change in fair value of
derivative liability
$7,530K
Net loss
-$104,901K
(-20.70%↓ Y/Y)
Total other
comprehensive income (loss)
-$1,005K
(-494.12%↓ Y/Y)
Total other income,
net
$11,268K
(62.04%↑ Y/Y)
Change in cumulative
translation adjustment
$3K
Collaboration
$135K
License
$6K
Interest expense
$3,462K
(490.78%↑ Y/Y)
Other expense, net
-$672K
Loss from operations
-$116,169K
(-23.76%↓ Y/Y)
Unrealized gain (loss) on
available-for-sale securities
-$1,008K
Total revenues
$141K
(95.83%↑ Y/Y)
Total operating
expenses
$116,310K
(23.82%↑ Y/Y)
Research and development
$77,631K
(1.04%↑ Y/Y)
Selling, general and
administrative
$38,679K
Back
Back
Income Statement
source: myfinsight.com
Viridian Therapeutics, Inc. DE (VRDN)
Viridian Therapeutics, Inc. DE (VRDN)